ReviewMolecular genetics and genomics : MGG2026
Unleashing lncRNA THOR: roles in cancer progression and clinical outlook.
Review in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testis-associated highly conserved oncogenic long non-coding RNA (lncRNA THOR) is highly expressed in normal testis tissue and in at least 15 types of tumours. Since its discovery in 2017, more than 20 studies have investigated its potential tumour-regulatory functions; however, a comprehensive review of these findings remains unavailable. This review aims to address this gap by synthesizing current research to provide an overview of the mechanisms through which lncRNA THOR regulates tumourigenesis and its potential clinical applications. In addition to enhancing insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) expression or activity, lncRNA THOR modulates several pathways, including protein kinase B (AKT), AMP-activated protein kinase (AMPK), ß-catenin, interleukin-6/signal transducer and activator of transcription 3 (IL-6/STAT3), and Yes-associated protein (YAP), thereby promoting tumourigenesis. In contrast to several other well-characterized lncRNAs, current literature does not clearly indicate that lncRNA THOR functions as a microRNA (miRNA) sponge or is involved in the progression of haematological malignancies, which warrants further investigation. Nonetheless, its consistent upregulation in diverse tumours and its association with poor clinical outcomes suggest that lncRNA THOR may serve as a diagnostic and prognostic biomarker. Targeting lncRNA THOR could also inhibit tumourigenesis. Consequently, large-scale clinical trials and mechanistic studies are required to validate the sensitivity, reliability, and specificity of lncRNA THOR as a biomarker or therapeutic target in cancer management.
Indexed as
Identifiers
41843189What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.